Bio-Techne Supports OverT Bio's $120K Grant for Advancements in Cell Therapy

Innovative Funding Fuels Cell Therapy Advancements at OverT Bio

OverT Bio, a New York City-based company dedicated to cell therapy, recently secures a $120,000 G-Rex Grant from ScaleReadyTM, a collaborative initiative that includes notable partners such as Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReadyTM. This grant is part of ScaleReady's substantial $20 million initiative aimed at propelling the development and manufacturing of Cell and Gene Therapy (CGT). The funding allows OverT Bio to advance its innovative technologies, specifically OverTargetTM and OverTCRTM, which are designed to create next-generation cell therapies targeting solid tumors. By optimizing cell manufacturing processes without incurring costs, OverT Bio accelerates its efforts in delivering advanced therapeutic solutions to cancer patients.

Mat Legut, PhD, CEO of OverT Bio, expresses profound gratitude for the G-Rex Grant, noting that it symbolizes recognition of the potential impact of their technology in providing life-saving treatments. He highlights that the grant facilitates access to newly developed Good Manufacturing Practice (GMP) closed system products, which are crucial for ensuring the scalability and cost-effectiveness of their therapies. This access is pivotal for OverT Bio as they aim to refine their manufacturing processes to meet the growing demand for effective cancer treatments.

Josh Ludwig, Commercial Director of ScaleReady, underscores that the G-Rex Grant Program reflects a commitment to advancing cell and gene-modified cell therapy. By supporting companies like OverT Bio, the initiative aims to help them save both time and financial resources while enhancing their attractiveness for investment. OverT Bio's approach combines data-driven methodologies with a focus on discovering new therapeutic targets and genetic enhancements, positioning the company at the forefront of developing effective cellular therapies that cater to patients with limited treatment options.

In addition to the grant, OverT Bio continues to build a strong foundation within the cell therapy industry, emphasizing the importance of collaborative efforts in advancing therapeutic technologies. Their commitment to innovation and patient-centric solutions aims to transform the landscape of cancer treatment, potentially leading to breakthroughs in therapies for solid tumors.

As OverT Bio leverages this funding, the collaboration between ScaleReady, Bio-Techne, and other partners highlights the growing ecosystem dedicated to enhancing the capabilities of cell and gene therapy. The support and resources provided through such grants are essential in driving the industry forward, ultimately benefiting patients awaiting new treatment options. For more details on OverT Bio’s initiatives and advancements, interested parties can visit their website at www.overt.bio.